3O'Brien SG,Guihot F,Larson RA,et al. lmatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia [J]. N Eng J Med, 2003,348( 1 ) :994-1004.
4Roy L,Guilhot J ,Krahnke T,et al. Survival advantage from i- matinib compared with the combination interferon-c plus cy- tarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials [J]. Journal of the American Society of Hematology, 2006,108 (5) : 1478- 1484.
5Fader! S,Talpaz M,Estrov Z,et al. Chronic myelogenous leukemia:biology and therapy [J]. Ann Intern Med, 1999,131 (2) : 207-219.
6Kujawski LA,Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia [J]. Cytokine & Growth Factor Reviews, 2007,18 (5-6) : 459-471.
7Talpaz M, Rakhit A, Rittweger K, et al. Phase I evaluation of a 40-kDa branced-chain long-acting pegylated IFN-c-2a with and without cytarabine in patients with chronic myel- ogenous leukemia [J]. Clin Cancer Res,2005,11 (1) :6247-6255.
